Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Fluoroquinolone use linked to heart problems, research suggests

After examining data from more than 9 million patients, researchers found that fluoroquinolone users were 2.4 times more likely to develop aortic or mitral regurgitation. 

antibiotic packets ss 19


People taking fluoroquinolone antibiotics are 2.4 times more likely to develop heart problems than people taking amoxicillin

Patients exposed to fluoroquinolone antibiotics, such as ciprofloxacin, are more than twice as likely to develop aortic or mitral regurgitation (backflow of blood into the heart), compared with patients taking amoxicillin, according to research published in the Journal of the American College of Cardiology (9 September 2019)[1].

Researchers examined adverse drug event data collected by the US Food and Drug Administration to identify cases of valvular regurgitation and through disproportionality analysis, discovered a stronger adverse drug event signal for fluoroquinolones compared with other medicines.

They also identified 12,505 cases of valvular regurgitation, which were matched with 125,020 controls from a sample of more than 9 million private health insurance claimants.

Current users of fluoroquinolones were 2.4 times more likely to develop aortic or mitral regurgitation compared with those taking amoxicillin. The risks of aortic or mitral regurgitation were highest with current use of fluoroquinolones (a prescription issued within the 30 days prior to the adverse event).

“It might be prudent to consider antibiotics that are chemically distinct to fluoroquinolones in patients with a previous history of valvular regurgitation who require antibacterial therapy,” the researchers concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207248

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.